Thus, modulating FPR2 not only with pro-resolving agonists, but also via selective blockade of Aβ interaction, may prove to be tactical research approaches in deciphering novel neuroprotective pathways in models of AD. This evidence concerns the gene FPR2 and Alzheimer disease.